At what enterprise value was NEMERA acquired in 2025?

You can find the full valuation details of NEMERA on mynth capital. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 13.4x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of NEMERA when it was acquired by LGT CAPITAL PARTNERS?

The exact EV/EBITDA multiple for NEMERA is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 13.4x. Join our community for free to access full valuation data and industry trends.

When was NEMERA acquired by LGT CAPITAL PARTNERS?

NEMERA was acquired by LGT CAPITAL PARTNERS in 2025.

What was the revenue of NEMERA at the time of the deal?

The revenue of NEMERA at the time of the deal is estimated to be in the range of 450M - 900M EUR. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the NEMERA acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the NEMERA deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.astorg.com/news/montagu-and-astorg-welcome-lgt-capital-partners-as-minority-shareholder-in-nemera

← DATABASE

Home Database Healthcare & PharmaNEMERA

08/2025

NEMERA

Acquired by

LGT CAPITAL PARTNERS

FRANCE Life Sciences / Medical Devices / Medical Consumables REV 450M - 900M EUR

NEMERA acquired by LGT CAPITAL PARTNERS

FRANCE Life Sciences / Medical Devices / Medical Consumables REV 450M - 900M EUR

Context

The deal represents a strategic investment by LGT Capital Partners, Montagu, and Astorg in Nemera, a leading global manufacturer of complex drug delivery devices. The transaction is expected to support Nemera's future growth plans, including enhancing its portfolio, expanding manufacturing capacity, and investing in innovation and operational excellence to meet rising global demand. The investment is closely aligned with the firms' focus on being leading global providers of capital solutions for private equity fund managers and their portfolio companies. With the support of its existing shareholders and the addition of LGT Capital Partners, Nemera is well-positioned to accelerate its growth trajectory and continue to scale globally, providing advanced solutions to its partners and patients worldwide. The deal demonstrates the confidence of the investors in Nemera's strategy and management team, and their commitment to supporting the company's next phase of development. The transaction is expected to have a positive impact on the market, as it will enable Nemera to further strengthen its position in the drug delivery devices market and expand its global footprint.

NEMERA, which reported an EBITDA margin of LOGIN in 2024, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (13.4x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Nemera (ex Rexam Healthcare Devices and Prescription Retail) is a leading provider of healthcare devices and pharmaceutical packaging solutions. The company's healthcare devices division designs and manufactures a range of products, including inhalers for asthma, insulin pens, and nasal pumps. The prescription retail division produces flacons and security caps for medications sold in pharmacies. With a strong presence in Europe and the United States, the company has a diverse portfolio of products that cater to various healthcare markets, including pulmonary, parenteral, ENT, dermal, and ophthalmic. The company's products are designed to improve patient outcomes and enhance the overall quality of healthcare. With a rich history and a strong commitment to innovation, Rexam Healthcare Devices and Prescription Retail has established itself as a trusted partner in the healthcare industry.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2024

2023

Other operations with NEMERA

Date	Acquirer	Target	Country	Sector	Deal Context
10/2018	ASTORG	NEMERA	FRANCE	Life Sciences	The acquisition of Nemera by Astorg Partners is a strategic move to capitalize on the company's strong market position, predictable revenue streams, and significant growth potential. The deal is driven by the attractiveness of Nemera's business model, which is characterized by long-term contracts, high recurrence rates, and a strong track record of EBITDA growth. Astorg Partners' investment in Nemera is expected to support the company's continued growth and expansion, with a focus on driving innovation, improving operational efficiency, and enhancing customer satisfaction. The transaction is also expected to provide a strong return on investment for Astorg Partners, given Nemera's solid financial performance and growth prospects. The deal process was highly competitive, with several strategic and financial buyers participating in the auction, and Astorg Partners' offer was distinguished by its attractive financial terms and compelling growth strategy.
02/2014	MONTAGU PRIVATE EQUITY	NEMERA	FRANCE	Life Sciences	The deal involves the carve-out of Rexam's healthcare devices and prescription retail divisions, which will be acquired by Montagu Private Equity. The transaction is subject to regulatory approval and is expected to be completed in the coming weeks. The strategic rationale behind the deal is to create a standalone company that can focus on the healthcare sector and leverage Montagu Private Equity's expertise and resources to drive growth and expansion. The deal is expected to enhance the competitiveness of the company and improve its market position, while also providing opportunities for innovation and investment in new products and technologies. The company's management team will work closely with Montagu Private Equity to develop a growth strategy that builds on the company's strengths and addresses the evolving needs of the healthcare market. With a strong foundation in place, the company is well-positioned to capitalize on emerging trends and opportunities in the healthcare sector, including the growing demand for innovative medical devices and pharmaceutical packaging solutions.

REFERENCES

Revenue range: 450M - 900M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of NEMERA by LGT CAPITAL PARTNERS are reserved for mynth community members. Register for free to unlock full data.

Authors: mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Target: nemera

Acquirer: lgt capital partners